methods for treating a patient having cancer, for increasing a proinflammatory immune effector cell population, for increasing the level of t-cell activation, for reducing the population of regulatory t-cells, for inhibiting the immunosuppressive function of regulatory t-cells, for the long-term enhancement of tumor-specific memory t-cell generation and to protect intratumoral immune cells from chemotherapy.

摘要

The addition of a fast acting short-acting selective cdk 4/6 inhibitor in a very specific dosing regimen for the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected finding is that specifically timed short pulsatile administration of a CDK 4/6 fast-acting short-half selective inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancerous microenvironment. .